NextCure's Avere merger financing rises to about $820M as SEC clears S-4 and vote is set for Dec 9

On November 10, 2026, NextCure reported Q3 results and said the financing for its proposed merger with Avere Therapeutics, developer of oral IL-23 therapy AVR-001, had grown to roughly $820 million. The SEC declared the S-4 effective on November 6, and stockholders vote on December 9, 2026. NextCure also handed the LNCB74 IND to LigaChem, restructured, and ended its SIM0505 study treatment, leaving $8.7 million in cash.

10 Nov 2026 · NextCure, Inc. NXTC · Company news

Company's press release (SEC filing): NextCure, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

NextCure's Avere merger financing rises to about $820M as SEC clears S-4 and vote is set for Dec 9

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq